23:23 , Aug 12, 2019 |  BC Extra  |  Company News

Aug. 12 Company Quick Takes: Jazz buying Cavion; plus Boehringer, AC Immune, Oncologie

Jazz gains essential tremor asset via Cavion takeout   Jazz Pharmaceuticals plc (NASDAQ:JAZZ) acquired Cavion Inc. for $52.5 million up front and up to $260 million in clinical, regulatory and sales milestones in a deal...
22:58 , Oct 11, 2018 |  BC Week In Review  |  Clinical News

Cavion planning Phase III for essential tremor candidate despite Phase II miss

Cavion Inc. (Charlottesville, Va.) said CX-8998 missed the primary endpoint in the Phase II T-CALM trial to treat moderate to severe essential tremor. Despite the miss, the company plans to start a Phase III trial...
21:55 , Oct 8, 2018 |  BC Extra  |  Clinical News

Cavion planning Phase III for essential tremor candidate despite Phase II miss

Cavion Inc. (Charlottesville, Va.) said CX-8998 missed the primary endpoint in the Phase II T-CALM trial to treat moderate to severe essential tremor. Despite the miss, the company plans to start a Phase III trial...
14:54 , Sep 11, 2018 |  BC Extra  |  Company News

Management tracks: Cheng joins Akero, bluebird COO leaving

Metabolic company Akero Therapeutics Inc. (Cambridge, Mass.) named former Gilead Sciences Inc. (NASDAQ:GILD) executive Andrew Cheng president and CEO. Cheng joined Gilead in 1999 to lead its development programs in HIV/AIDS and became an EVP...
23:04 , Aug 15, 2017 |  BC Extra  |  Company News

Management tracks: Cerecor, Allakos, Epizyme, Merrimack

Neurology play Cerecor Inc. (NASDAQ:CERC) said Uli Hacksell retired as president and CEO. CBO John Kaiser will be interim CEO while the company searches for a permanent replacement. Antibody play Allakos Inc. (San Carlos, Calif.)...
17:37 , Mar 30, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Cell culture and mouse studies identified calcium channel T-type and potassium channel inhibitors that could help treat glioblastoma. Screening of a library of ion channel blockers against primary human glioblastoma cell lines...
23:51 , Jan 6, 2017 |  BC Extra  |  Financial News

Cavion raises $26.1M series A

Cavion Inc. (Charlottesville, Va.) raised $26.1 million in a series A round co-led by Lilly Ventures and Novartis Venture Fund. Enso Ventures also participated, as did undisclosed existing investors. The company is developing T-type calcium...
22:33 , Jan 6, 2017 |  BC Week In Review  |  Financial News

Cavion completes venture financing

Cavion raised $26.1 million in a series A round co-led by Lilly Ventures and Novartis Venture Fund. Enso Ventures and existing investors also participated. Cavion Inc. , Charlottesville, Va. ...
08:00 , Nov 16, 2015 |  BC Week In Review  |  Financial News

Cavion completes venture financing

Cavion LLC , Charlottesville, Va.   Business: Cancer, Neurology   Date completed: 2015-11-10   Type: Venture financing   Raised: $5 million   Investors: Existing investors; new investors   Note: The financing is convertible note.  ...
07:00 , Oct 20, 2014 |  BC Week In Review  |  Clinical News

Mibefradil dihydrochloride: Phase Ib started

Cavion said Yale University began an open-label, dose-escalation, U.S. Phase Ib trial to evaluate 150-350 mg/day oral mibefradil given over 4 daily doses with hypofractionated radiation therapy for 17 days in about 24 adults with...